The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/adding-chemo-osimertinib-doubles-progression-free-survival-2026a10009fy?src=rss
Author :
Publish date : 2026-03-27 12:51:00
Copyright for syndicated content belongs to the linked Source.